RCT: A single dose of a novel adenovirus type 5 vectored SARS-CoV-2 vaccine was safe and had 57.5% efficacy against symptomatic Covid-19 and 91.7% efficacy against severe disease in adults.
13 Jan, 2022 | 08:44h | UTCCommentaries:
Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine – The Lancet